Challenging the visceral fat paradigm: abdominal subcutaneous adiposity dominates cardiometabolic risk in young, lean Indians

Rucha SH. Wagh[1,2], Rupali U. Bawdekar[1], Wareed Alenaini[3], Rashmi B. Prasad[4], Caroline HD. Fall[5], E Louise Thomas[3], Jimmy D Bell[3], Satyajeet P. Khare[2*], Yajnik CS[1*].

[1]Diabetes Unit, King Edward Memorial Hospital and Research Centre, Pune, India.

[2]Symbiosis School of Biological Sciences, Symbiosis International (Deemed) University, Pune, India

[3]Research Centre of Optimal Health, School of Life Sciences, University of Westminster, UK.

[4]Lund University Diabetes Centre, Lund University, Sweden

[5]MRC-Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK

* shared senior authorship

Corresponding Author

Dr Chittaranjan S Yajnik

Diabetes Unit, KEM Hospital and Research Centre,

Rasta Peth, Pune, Maharashtra 411011 India

E-mail ID: csyajnik@gmail.com

Mobile: +91-9822847481

ORCiD: 0000- 0002- 2911- 2378

Research Insights

What is currently known about this topic? (max. 3 highlights, each < 100 characters) Indians have higher central obesity-adiposity than Europeans at similar BMI. Western data links VAT with cardiometabolic risk, while ASAT is protective. VAT & ASAT risk patterns vary across native and migrant South Asians.
What is the key research question? (formatted as a question, < 100 characters) How do VAT and ASAT associate with cardiometabolic risk in lean rural Indian youth?
What is new? (max. 3 highlights, each < 100 characters) ASAT shows stronger links with cardiometabolic risk than VAT in rural Indian youth. ASAT may contribute to high diabetes and CVD risk at low BMI in young Indians.
How might this study influence clinical practice? (max. 1 highlight, < 100 characters) Early-life ASAT accumulation may raise later cardiometabolic risk, supporting early prevention strategies.

Abstract

Background: Visceral adiposity is widely regarded as the pathogenic component of central obesity in cardiometabolic disease. However, emerging evidence suggests that abdominal subcutaneous adiposity may also confer metabolic risk in South Asian populations, although data in young, lean individuals are scarce. We investigated associations of MRI-measured abdominal subcutaneous adipose tissue (ASAT) and visceral adipose tissue (VAT) with cardiometabolic risk markers in young rural Indian adults.

Methods: We quantified ASAT and VAT using MRI in 590 participants (310 men) aged 18 years from the Pune Maternal Nutrition Study cohort. Sex-specific multiple regression models were used to examine associations with glucose–insulin indices, blood pressure, lipids, adipokines, and inflammatory markers.

Results: ASAT showed broad and consistent associations with adverse cardiometabolic profiles, including higher 120-min glucose, dyslipidaemia, elevated blood pressure, leptin, CRP and leukocyte count, and lower insulin sensitivity and adiponectin, particularly in men; in women, ASAT was associated with most cardiometabolic risk markers except HDL-cholesterol. In contrast, VAT was associated with fewer risk markers and exhibited weaker,

sex-specific patterns of association. Across outcomes, associations with ASAT were generally stronger than those observed for VAT.

Conclusions: In young, lean Indians, abdominal subcutaneous adiposity exhibits stronger associations with insulin resistance, dyslipidaemia and inflammation than visceral adiposity, challenging the prevailing VAT-centric paradigm derived largely from Western populations. These findings provide human evidence that the hierarchy of metabolic risk across abdominal fat depots is population-specific. This suggests genetic and early-life risk stratification, and supports early targeted preventive strategies.

INTRODUCTION

Obesity is a well-known global health burden with an ever-increasing prevalence worldwide (currently 43%) (1). Its prevalence is also substantial (23%) in low- or middle-income countries like India, which have undergone a rapid nutritional transition against a background of multigenerational cycles of undernutrition (1, 2). Obesity is commonly assessed using BMI and simple anthropometric measures such as waist circumference, but these metrics provide only crude proxies for body composition. Obesity, characterised by excess adiposity is a major determinant of health and plays a central role in increasing the risk of cardiometabolic diseases (3). Adiposity is insufficiently captured by BMI and other anthropometric variables. This has led to a change in terminology to 'Adiposity-based Chronic Diseases (ABCD)', which focuses on dysfunction in the mass, distribution and function of adipose tissues (4).

Previous studies in middle-aged Indians have highlighted the association of central obesity-adiposity (waist circumference, waist hip ratio, truncal skinfolds) with insulin resistance and type 2 diabetes (5, 6). Further, studies using imaging techniques have explored depot-specific associations of abdominal adipose tissue (visceral adipose tissue, VAT vs subcutaneous adipose tissue, ASAT) with cardiometabolic risk. In western population, VAT has been consistently associated with increased risk of insulin resistance, dyslipidaemia, type 2 diabetes, inflammation, and other cardiometabolic diseases (7); in contrast, ASAT has often been considered metabolically inert or even protective (8). Studies in migrant Indians have suggested adverse associations of ASAT (9). Indian studies exploring such investigations have reported variable associations between VAT and ASAT, and metabolic dysfunction which may be attributable to differences in age and metabolic status of the population investigated (10-13). In relatively younger adults, both VAT and ASAT are associated with clinical outcomes whereas in older adults, the associations are limited to VAT.

Based on this evidence, we hypothesize that both ASAT and VAT are associated with cardiometabolic risk markers in young adults. We investigated associations of MRI-measured ASAT and VAT with a range of cardiometabolic risk markers in apparently healthy, relatively lean, and young Indian adults (18 years of age) in the Pune Maternal Nutrition Study (PMNS), a rural community-based birth cohort.

METHODS

Overview of the Cohort

The PMNS is a preconceptional birth cohort set up in 1993 in six villages around Pune, India (14). Briefly, 2466 married non-pregnant women (F0 generation) were followed-up, and 797 who became pregnant were recruited into the study and delivered live singleton births (F1). Serial data on a range of anthropometric and metabolic parameters is available on the F1 generation. At 18-years, 663 participants (356 men) were followed-up and abdominal MRI was performed in 599 (310 men) (Figure 1).

Measurements at 18-years

Anthropometry measurements

Height, weight, waist, and hip circumferences were measured using standardised methods by trained staff. Body mass index (BMI) was calculated as weight (kg)/(Height (m))^2, WHR was calculated as waist circumference/hip circumference.

MRI measurements

Magnetic Resonance Imaging was performed using a 1.5T Siemens, MAGNETOM Harmony scanner (Siemens corporation, Munich, Germany). Axial 10 mm thick abdominal slices were obtained at 11 mm gap using T1 weighted spin echo sequence with 100-ms repetition time, 7.49ms echo time and one-half excitation for all acquisitions. Three slices were obtained for each acquisition sequence centered at the L4-L5 vertebral disc. The duration of each

acquisition was 36s. All images were analysed using Slice-O-Matic (Tomovision, Montreal, QC, Canada) for ASAT and VAT quantification (15) with adipose tissue area recorded in cm^2. The ASAT and VAT segmentation method was based on two main tools; image morphology and manual editing to label regions as ASAT or VAT respectively, performed by experts.

Biochemical measurements

Biochemistry measurements included glucose and insulin during an OGTT (glucose load: 75g anhydrous glucose) - fasting, and 30- and 120-minutes post-load. Insulin sensitivity was estimated during the OGTT using the Matsuda Index (16). Early insulin secretion was estimated using the insulinogenic index (17). Disposition index (a measure of β cell function adjusted for prevailing insulin sensitivity) was calculated as the product of insulinogenic index and Matsuda index. Triglycerides, HDL, and cholesterol concentrations were also measured using standardised enzymatic assays (Hitachi 902, Roche Diagnostics, GmbH, Germany), LDL-c was measured using the Friedewald equation. We also calculated the ratio of TG:HDL-c as a marker of metabolic dysfunction. Inflammatory markers like leptin and adiponectin were measured using ELISA (Alpco Diagnostics, Salem, NH 03079), c-reactive protein (CRP) was measured by high-sensitivity ELISA (United Biotech. Mountain View, CA, USA).

Definitions

Underweight and overweight/obesity were defined using BMI as per WHO criteria (18). Central obesity was defined as a waist circumference ≥ 90 cm for men and ≥ 80 cm for women. According to ADA 2014 criteria (19), prediabetes was defined based on the OGTT as impaired fasting glucose and/or impaired glucose tolerance (fasting glucose ≥ 100 mg/dl and/or 120min glucose ≥ 140 mg/dl). Dyslipidaemia was defined as triglycerides > 150 mg/dl and/or HDL<40 mg/dL for men and <50 mg/dL for women, and hypertension was defined as

blood pressure ≥ 130/85 mm/Hg. Metabolic syndrome was defined according to IDF criteria (Central obesity and any two of the following: triglycerides ≥ 150mg/dl; HDL-c < 40 mg/dl in men, < 50 in women; BP ≥ 130/85; fasting plasma glucose ≥ 100) (20).

Statistical analysis

Data are presented as median (25th – 75th percentile). Skewed variables were log transformed. All variables were standardised (mean zero, standard deviation unity) adjusting for age and separately for sexes, to enable comparison of effect sizes. The primary analysis was to investigate associations between MRI fat measurements (VAT & ASAT) and other cardio-metabolic risk factors separately for men and women. For this analysis, we performed multiple linear regression models with both ASAT and VAT included in the same model (VIF<5). Furthermore, to compare the coefficients of ASAT and VAT for each outcome, we performed Wald's test presented by Z statistics and p-value. Sensitivity analysis was conducted with additional adjustment of height, BMI (general obesity), and waist circumference (central obesity), added separately to the models including ASAT and VAT.

Given the small numbers for metabolic syndrome (12/590), to explore the associations of VAT and ASAT with metabolic syndrome, we performed Firth's penalized logistic regression to reduce small-sample bias. Simple logistic regression was used for prediabetes as an outcome. A nominal p-value < 0.05 was considered significant for all the above-mentioned analysis.

For comparing published data from studies of native and migrant South Asians, we selected studies which included image-derived ASAT and VAT quantification (MRI/CT). We corresponded with the authors to share their metadata on age, BMI, amount of absolute ASAT and VAT, and the ASAT/VAT ratios. There was heterogeneity in the protocols across studies (area vs volume; varying slice locations/numbers). Thus, to enable relative comparison of cohort positioning rather than absolute harmonization, we standardized study-

level means to z-scores within each phenotype and compared the relative distribution of BMI, VAT, ASAT and ASAT:VAT ratio across cohorts. We included 7 studies on which the data was received out of 10 studies approached.

All statistical analysis was performed using SPSS v26 and R v4.4.1.

RESULTS

Characteristics of participants (Table 1):

Of 663 participants in the 18-year follow-up cohort, abdominal MRI scans were performed for 599 participants, of which 8 scans were excluded due to poor image quality (artefacts and motion-distortions), and 1 female with MODY diabetes. The final analysis included 590 participants (310 men) with complete data (Figure 1). The median age for the men was 18.2 (17.9-18.6) years and women 17.6 (17.2-18.1) years. Median BMI was 19.0 (17.2, 21.3) kg/m^2 in men and 18.1 (16.8, 20.2) kg/m^2 in women; 41.1% of men and 54.4% of women were underweight; 9.1% of men and 4.3% of women were overweight/obese. Central obesity (waist circumference) was present in 6.1% of men and 5% of women. Forty percent of men and 19.2% of women were glucose intolerant. Men had a greater prevalence of IFG (28.4 % vs 8.5%) while IGT was more prevalent in women (8.2% vs 4.2%). Thirty-two percent of men and 38.4 % of women had dyslipidaemia. None of the participants were hypertensive. A small number (12/590, 2%) would be classified as having metabolic syndrome as per IDF criteria.

MRI data revealed that women had a higher absolute total abdominal fat area (473.8 cm^2 vs men 408.5 cm^2), ASAT area (311.2 cm^2 vs men 217.6 cm^2), ASAT-to-VAT ratio (1.9 vs men 1.2) compared to men, while men had a higher VAT area (194.5 cm^2 vs women 164.7 cm^2) (Table 1, Figure 2). As a group, the participants had a higher ASAT area (257.8 cm^2) compared to VAT (179.9 cm^2).

ASAT has stronger associations than VAT with cardiometabolic risk markers

Given known sex differences in body composition, results are presented by sex and then in combined models.

In men, VAT showed positive associations with fasting glucose, total cholesterol, leptin, and systolic blood pressure, and inverse associations with the Matsuda index and adiponectin. ASAT was positively associated with 120-min glucose, triglycerides, total and LDL-cholesterol, triglyceride:HDL-c ratio, systolic and diastolic blood pressure, leptin, CRP, and leukocyte count, and inversely with the Matsuda index and adiponectin (Table 2, Figure 3). In women, VAT was positively associated with the triglyceride:HDL-c ratio and inversely with adiponectin, whereas ASAT showed positive associations with systolic and diastolic blood pressure, triglycerides, total and LDL-cholesterol, triglyceride:HDL-c ratio, leptin, CRP, and leukocyte count, and inverse associations with the Matsuda index and adiponectin (Table 2, Figure 3). Across sexes, associations were generally stronger for ASAT than for VAT, supported by Wald tests.

Additional adjustment for height did not alter these findings. Further adjustments for general (BMI) and central (waist circumference) obesity moderately attenuated the associations, though the dominance of ASAT over VAT remained.

Despite the low prevalence of metabolic syndrome (12/592), ASAT - but not VAT - was associated with metabolic syndrome (OR 2.72, 95% CI 1.81-4.26 vs. 1.57, 0.85-2.93). Neither depot was associated with prediabetes (ASAT: OR 1.13, 95% CI 0.93-1.34; VAT: OR 1.12, 0.92-1.36).

DISCUSSION

This is the first population-based Indian study using MRI to quantify abdominal fat compartments in a large sample of apparently healthy, lean, young rural adults. Traditionally, such populations are expected to have a low burden of cardiometabolic risk. However, nearly

30% had prediabetes on OGTT, previously linked to poor intrauterine growth and higher maternal glycaemia (21). The present study examined associations of MRI-measured abdominal adipose depots with cardiometabolic risk markers at 18 years. We found consistently stronger associations of ASAT with glucose-insulin indices, blood pressure, lipids, adipocytokines, and inflammatory markers than those observed for VAT in both the sexes. In contrast, VAT was associated with fewer risk factors and displayed pronounced sex-specific patterns, with more associations in men than in women. Metabolic syndrome was significantly associated with ASAT but not VAT. These findings contrast with Western populations, where VAT is the dominant correlate of cardiometabolic risk (7, 22, 23), and with Chinese data showing adverse associations of the VAT/ASAT ratio with cardiovascular outcomes (24). Together, these findings highlight population-specific differences in depot-related cardiometabolic risk.

Evidence for differential associations of ASAT and VAT with cardiometabolic risk in South Asians is heterogeneous. Studies in relatively young, non-obese North Indian participants report stronger associations of ASAT than VAT with dyslipidaemia, hypertension, and diabetes (10, 11), consistent with our observations in a younger and leaner rural cohort. In contrast, studies in older South Indians indicate a more prominent role of VAT in relation to metabolic syndrome (12, 13). These discrepancies suggest that age, glycaemic status, and population context influence adipose tissue distribution and its metabolic consequences. Migrant South Asians exhibit greater total, subcutaneous, and visceral abdominal adiposity than BMI-matched Europeans (25-30), consistent with the “thin–fat” phenotype and heightened insulin resistance and cardiometabolic risk.

Sex differences in adipose distribution are well recognised, with women having greater subcutaneous fat and men greater visceral fat (31). In PMNS, both ASAT and VAT were

associated with metabolic risk in men, whereas ASAT was the dominant correlate in women (Figure 3). These differences likely reflect the influence of sex hormones on adipose tissue distribution, metabolism, and energy homeostasis (32, 33).

While VAT is traditionally linked to systemic inflammation (34), our findings indicate that ASAT is also associated with inflammatory markers, including CRP, total leukocyte count, leptin, and lower adiponectin, suggesting inflammation as a potential pathway linking ASAT to cardiometabolic risk in South Asians. When compared with other South Asian cohorts across a wide age range (Figure 4), PMNS participants were the youngest and had the lowest BMI, yet had comparable ASAT and VAT (13, 29, 35-37), consistent with the thin–fat phenotype. Low lean mass, reflecting reduced metabolic capacity, combined with excess abdominal adiposity, representing increased metabolic load, may underlie early cardiometabolic risk, in line with the capacity-load model (34, 38). Such a phenotype may be rooted in intrauterine programming, whereby adaptations to nutritional scarcity favour fat accumulation that becomes maladaptive with nutritional adequacy (Figure 5) (39, 40).

Adipose depots arise from distinct developmental programs. Early-established SAT may provide a protective lipid storage depot, whereas later-developing VAT and deep SAT are more prone to hypertrophic expansion, inflammation, and insulin resistance (41-43). PMNS participants were born small (mean 2.7 kg) but relatively adipose compared with English infants (mean 3.5 kg), with evidence of greater ASAT from birth into childhood, and higher insulin resistance (44, 45). These findings suggest distinct developmental programming of ASAT due to intrauterine nutritional and metabolic exposures, potentially amplified by rapid nutritional transition.

Abdominal adipose tissue comprises superficial SAT, deep SAT, and VAT, which exhibit a gradient of metabolic risk (34). VAT has the most adverse metabolic profile, while deep SAT

displays VAT-like dysfunction, and superficial SAT retains greater adipogenic capacity and metabolic buffering (43, 46). Although VAT is consistently associated with adverse metabolic outcomes in Western and migrant South Asian populations, emerging evidence suggests that deep SAT may also contribute substantially to cardiometabolic risk (9). As we could not distinguish superficial from deep ASAT, the stronger associations with ASAT in our study may reflect a predominant contribution of deep SAT. While ASAT has traditionally been considered metabolically neutral or protective (47), recent European data linking changes in ASAT thickness to cardiovascular disease risk suggest a more complex role (48). Histological studies demonstrate larger, hypertrophic adipocytes and reduced expandability in ASAT among South Asians compared with Europeans (9, 28, 29). Complementing these findings, multi-omics analyses reveal overlapping pro-inflammatory and lipogenic gene expression signatures in both ASAT and VAT in Indians (9, 49-51), contrasting with Western populations where VAT predominates as the primary driver of risk (22, 52). These data point to population-specific adipose tissue morphology and molecular programming as potential explanations for the heightened metabolic susceptibility of ASAT in Indians (Figure 5).

Strengths of this study include MRI-based quantification of abdominal adipose depots in nearly 600 participants from a well-characterised birth cohort, comprehensive cardiometabolic phenotyping, and assessment at a young age before overt disease and treatment effects, thereby reducing reverse causality. Limitations include the observational design, inability to distinguish superficial and deep ASAT, use of epidemiological rather than gold-standard measures of insulin action and secretion, and cautious interpretation of cross-study comparisons due to methodological differences.

In conclusion, in contrast to Western populations, abdominal subcutaneous adiposity appears to be a stronger correlate of dysglycaemia, inflammation, and adverse cardiometabolic

profiles than visceral adiposity in young native rural Indians. These findings challenge prevailing paradigms and underscore the need for age- and ethnicity-specific approaches to cardiometabolic risk assessment, prevention, and intervention. Further mechanistic studies are required to elucidate the developmental, cellular, and molecular pathways underlying depot-specific programming of adipose tissue and its long-term metabolic consequences.

Declarations:

Ethics approval and consent to participate

The study was approved by local village leaders and the Ethics Committee of the KEM Hospital Research Centre (KEMHRC/VSP/Dir. Off/EC12465). An informed consent form was signed by all participants. Ethical approvals pertaining to this secondary analysis were obtained from KEM: KEMHRC/RVM/EC/1037 and SIU: EC/NEW/IND/2024/MH/0477.

Data Availability Statement

The dataset supporting the conclusions of this article is available for additional analyses by applying to the corresponding author with a 200-word plan of analysis. Data sharing is subject to KEM Hospital Research Centre administrative approvals and permission from the Government of India's Health Ministry Screening Committee

Competing interests

The authors declare that they have no competing interests.

Funding

The PMNS was funded by the Wellcome Trust, UK (038128/Z/93, 059609/Z/99, 079877/Z/06/Z, 098575/B/12/Z and 083460/Z/07/Z); the Medical Research Council, UK (MR/J000094/1); and the Department of Biotechnology, Government of India (BT/PR-6870/PID/20/268/2005). Rashmi Prasad has received funding support from VINNOVA (2023-04234) and VR (2021-02623). RW is supported by a senior research fellowship from the Council of Scientific and Industrial Research, India

Authors' contributions

CSY and CHDF conceptualised the study. RSHW was involved in statistical analysis. RB and WA contributed to MRI image data cleaning and image segmentation. ELT and JDB set up and supervised the MRI image segmentation, and shared the summary statistics for migrant SA from different UK studies. CSY and RSHW prepared the manuscript. RP and SK

were involved in the critical review of the manuscript. All authors were involved in the review of the manuscript, and approved the final version of the manuscript. CSY is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis

Acknowledgements

We thank the participants, collaborators, funding agencies and the Diabetes Unit staff for their contribution towards this study. We would also like to thank the authors for the following cohorts – MASALA (Alka Kanaya), MolSHARE (Sonia Anand), CURES (RM Anjana) - for sharing the summary statistics plotted in Figure 3.

Table 1: Characteristics of the participants

Measures	Men (n=310)		Women (n=280)	
Age (years)	18.2	(17.9, 18.6)	17.6	(17.2, 18.1)
Height (cm)	169.6	(165.5, 173.7)	157.0	(153.3, 160.7)
Weight (kg)	55.49	(49.39, 62.02)	44.8	(41.3, 49.9)
Body Mass Index (BMI, kg/m^2)	19.0	(17.2, 21.3)	18.7	(16.8, 20.2)
Underweight (BMI < 18.5)	127	(41.1)	153	(54.4)
Overweight/Obese (BMI > 25)	28	(9.1)	12	(4.3)
Waist circumference (cm)	71.0	(66.5, 77.5)	67.5	(63.3, 71.8)
Hip circumference (cm)	87.0	(82.3, 92.4)	86.1	(82.0, 89.9)
WHR	0.82	(0.79, 0.85)	0.78	(0.75, 0.81)
Sum of skinfolds (mm)	32.6	(24.0, 52.3)	57.3	(42.3, 79.9)
MRI ASAT (cm^2)	217.6	(152.2, 363.8)	311.2	(219.3, 442.6)
MRI VAT (cm^2)	194.5	(158.5, 242.3)	164.7	(132.0, 204.3)
MRI total abdominal area (cm^2)	408.5	(325.6, 608.8)	473.8	(365.9, 623.9)
MRI ASAT/VAT ratio	1.2	(0.9, 1.8)	1.9	(1.4, 2.7)
Fasting glucose (mmol/l)	5.39	(5.17, 5.61)	5.17	(4.94, 5.33)
30-min glucose (mmol/l)	8.28	(7.56, 9.17)	8.33	(7.50, 9.06)
120-min glucose (mmol/l)	6.11	(5.33, 7.01)	6.33	(5.50, 7.11)
Fasting insulin (pmol/l)	62.5	(45.1, 88.9)	75.0	(57.6, 94.5)
30-min insulin (pmol/l)	552.1	(376.4, 810.6)	675.7	(452.8, 895.4)
120-min insulin (pmol/l)	319.5	(188.9, 485.6)	456.4	(288.9, 671.5)
Impaired fasting glucose (IFG)	88	(28.4)	24	(8.5)
Impaired glucose tolerance (IGT)	13	(4.2)	23	(8.2)
Prediabetes (IFG+IGT)	124	(40)	55	(19.6)
Insulinogenic index	1.70	(1.39, 2.07)	1.69	(1.36, 2.07)
Matsuda index	13.2	(9.46, 19.12)	11.76	(8.81, 15.74)

Measures	**Men (n=310)**		**Women (n=280)**	
Disposition Index	4.31	(3.81, 4.83)	4.12	(3.71, 4.57)
Systolic BP (mmHg)	112	(106, 119)	106	(100, 110)
Diastolic BP (mmHg)	58	(53, 64)	61	(57, 65)
Cholesterol (mmol/l)	3.14	(2.79, 3.59)	3.44	(3.03, 3.79)
HDL (mmol/l)	0.98	(0.85, 1.09)	1.09	(0.96, 1.24)
Triglycerides (mmol/l)	0.69	(0.53, 0.86)	0.60	(0.49, 0.75)
Leptin (ng/mL)	2.7	(1.2, 6.7)	15.8	(10.1, 25.1)
Adiponectin (ng/mL)	4.7	(3.7, 5.9)	5.1	(4.0, 6.5)
TLC (10^3/µL)	5.8	(5.1, 6.6)	6.3	(5.6, 7.4)
C-reactive protein	0.08	(0.06, 0.13)	0.07	(0.05, 0.11)

Data is presented as median (25th-75th) or N (%) where appropriate.

Table 2: Associations of MRI measurements with cardiometabolic risk markers separately for sexes.

	Males					Females				
	ASAT		VAT		Difference b/w coefficients	ASAT		VAT		Difference b/w coefficients
Outcome	**β (SE)**	**p-value**	**β (SE)**	**p-value**	**Z (p-value)**	**β (SE)**	**p-value**	**β (SE)**	**p-value**	**Z (p-value)**
Fasting glucose	0.016 (0.051)	0.752	**0.107 (0.051)**	**0.037**	-1.26 (0.207)	0.055 (0.079)	0.488	0.088 (0.079)	0.268	-0.29 (0.769)
120-minute glucose	**0.154 (0.067)**	**0.022**	0.065 (0.067)	0.330	0.95 (0.343)	0.110 (0.069)	0.111	-0.098 (0.068)	0.155	**2.14 (0.032)**
Insulinogenic Index	0.059 (0.069)	0.390	-0.042 (0.069)	0.540	1.04 (0.297)	-0.023 (0.068)	0.739	-0.015 (0.067)	0.822	-0.08 (0.937)
Matsuda Index	**-0.490 (0.058)**	**0.000**	**-0.170 (0.058)**	**0.003**	**-3.92 (0.000)**	**-0.172 (0.064)**	**0.008**	-0.046 (0.063)	0.464	-1.41 (0.158)
Disposition Index	**-0.334 (0.063)**	**0.000**	**-0.135 (0.063)**	**0.033**	-2.23 (0.026)	**-0.200 (0.067)**	**0.003**	0.031 (0.066)	0.641	**-2.45 (0.014)**
Systolic BP	**0.191 (0.069)**	**0.006**	**0.237 (0.070)**	**0.001**	-0.47 (0.639)	**0.235 (0.055)**	**0.000**	0.015 (0.055)	0.792	**2.84 (0.005)**
Diastolic BP	**0.325 (0.073)**	**0.000**	0.035 (0.073)	0.631	**2.82 (0.005)**	**0.284 (0.050)**	**0.000**	-0.019 (0.050)	0.706	**4.25 (0.000)**
Triglycerides	**0.294 (0.066)**	**0.000**	0.119 (0.066)	0.072	1.87 (0.061)	**0.147 (0.061)**	**0.016**	0.056 (0.061)	0.353	1.06 (0.291)
Cholesterol	**0.223 (0.064)**	**0.001**	**0.144 (0.064)**	**0.025**	0.89 (0.376)	**0.164 (0.065)**	**0.012**	-0.041 (0.065)	0.527	**2.24 (0.025)**
HDL-cholesterol	-0.036 (0.068)	0.602	-0.009 (0.068)	0.898	-0.28 (0.781)	-0.049 (0.063)	0.434	**-0.166 (0.063)**	**0.009**	1.30 (0.193)
LDL-cholesterol	**0.379 (0.066)**	**0.000**	0.029 (0.064)	0.645	**3.82 (0.000)**	**0.183 (0.064)**	**0.005**	0.014 (0.064)	0.827	1.86 (0.063)
TG:HDL-c	**0.252 (0.067)**	**0.000**	0.099 (0.067)	0.141	1.60 (0.110)	**0.140 (0.060)**	**0.020**	**0.120 (0.060)**	**0.046**	0.24 (0.812)
Leptin	**0.877 (0.048)**	**0.000**	**0.184 (0.048)**	**0.000**	**10.18 (0.000)**	**0.490 (0.032)**	**0.000**	-0.022 (0.032)	0.495	**11.32 (0.000)**
Total Adiponectin	**-0.267 (0.065)**	**0.000**	**-0.132 (0.063)**	**0.038**	-1.49 (0.136)	**-0.239 (0.066)**	**0.000**	0.011 (0.065)	0.868	**-2.71 (0.007)**
Total leukocyte count	**0.201 (0.063)**	**0.001**	0.033 (0.063)	0.593	1.89 (0.058)	**0.176 (0.068)**	**0.010**	-0.005 (0.068)	0.944	1.89 (0.059)
C-reactive protein	**0.128 (0.064)**	**0.047**	0.040 (0.064)	0.534	0.97 (0.330)	**0.180 (0.074)**	**0.016**	-0.066 (0.074)	0.371	**2.35 (0.019)**

Data are presented as beta coefficient (standard error, SE) using multiple linear regression analysis. All variables were converted to standardised residuals before analysis. Difference between the coefficients was calculated using Wald's test and presented as Z statistics (p-value).

Figure legends

Figure 1. STROBE flow diagram of Pune Maternal Nutrition Study. # 590 participants included in analysis were similar to 73 who were excluded, except for 120 min OGTT glucose.

Figure 2. Distribution of ASAT and VAT among men and women of the PMNS.

Figure 3. Associations between VAT, ASAT, and the metabolic profile of the participants adjusted for age and separately for sexes. Sankey diagram showing the associations (beta estimates) between VAT, ASAT, and the metabolic profile of the participants separately for sexes – (a) Men, (b) Women. Colours denote significance and direction of association, red for positive, blue for negative associations. NS, non-significant associations indicated by grey colour. Comparison between the beta coefficients of ASAT and VAT was performed using Wald test, and significance ($p<0.05$) is denoted by orange star.

Figure 4. Distribution of BMI, ASAT, VAT, and ASAT/VAT ratio across South-Asian Indian population (Native + Migrant). Study level means were standardised to z-scores within each phenotype before plotting across age. Cohorts – native SA (light colour): PMNS, CRISIS, CURES; migrant SA (dark colour): migrant SA from different UK studies (UK SA 1, UK SA 2), Mediators of Atherosclerosis in South Asians Living in America (MASALA) and Multi-Ethnic Study of Atherosclerosis (MESA), USA; The Molecular Study of Health and Risk in Ethnic Groups (MolSHARE), Canada

Figure 5. Population-specific pattern of cardiometabolic risk and abdominal fat depots. Western populations stress visceral adipose tissue (VAT) as the primary pathogenic abdominal fat depot. In contrast, our MRI-based analyses in young, lean rural Indians demonstrate stronger and broader associations of abdominal subcutaneous adipose tissue (ASAT) with cardiometabolic risk markers. This conceptual schematic highlights a context-dependent abdominal fat risk hierarchy, potentially shaped by genetics, early-life programming and population-specific adipose tissue biology.

References

1. World Health Organization. Obesity and overweight Geneva: World Health Organization; 2025 [updated 2025/05/07. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
2. UNICEF India. India: Overweight and obesity rising across all ages – from youngest children to adults. 2025 2025/09/11.
3. Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221–62.
4. Garvey WT. Adiposity-Based Chronic Disease. In: Mechanick JI, Kushner RF, editors. Lifestyle Medicine. Cham: Springer; 2025. p. 11–29.
5. Shelgikar KM, Hockaday TD, Yajnik CS. Central rather than generalized obesity is related to hyperglycaemia in Asian Indian subjects. Diabet Med. 1991;8(8):712–7.
6. Ganpule-Rao A, Joglekar C, Patkar D, Chinchwadkar M, Bhat D, Lubree H, et al. Associations of trunk fat depots with insulin resistance, beta cell function and glycaemia--a multiple technique study. PLoS One. 2013;8(10):e75391.
7. Neeland IJ, Ross R, Despres JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715–25.
8. Schoettl T, Fischer IP, Ussar S. Heterogeneity of adipose tissue in development and metabolic function. J Exp Biol. 2018;221(Pt Suppl 1).
9. Marinou K, Hodson L, Vasan SK, Fielding BA, Banerjee R, Brismar K, et al. Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care. 2014;37(3):821–9.
10. Goel K, Misra A, Vikram NK, Poddar P, Gupta N. Subcutaneous abdominal adipose tissue is associated with the metabolic syndrome in Asian Indians independent of intra-abdominal and total body fat. Heart. 2010;96(8):579–83.
11. Misra A, Anoop S, Gulati S, Mani K, Bhatt SP, Pandey RM. Body Fat Patterning, Hepatic Fat and Pancreatic Volume of Non-Obese Asian Indians with Type 2 Diabetes in North India: A Case-Control Study. PLoS One. 2015;10(10):e0140447.
12. Sandeep S, Gokulakrishnan K, Velmurugan K, Deepa M, Mohan V. Visceral & subcutaneous abdominal fat in relation to insulin resistance & metabolic syndrome in non-diabetic south Indians. Indian J Med Res. 2010;131:629–35.
13. Anjana M, Sandeep S, Deepa R, Vimaleswaran KS, Farooq S, Mohan V. Visceral and central abdominal fat and anthropometry in relation to diabetes in Asian Indians. Diabetes Care. 2004;27(12):2948–53.
14. Rao S, Yajnik CS, Kanade A, Fall CH, Margetts BM, Jackson AA, et al. Intake of micronutrient-rich foods in rural Indian mothers is associated with the size of their babies at birth: Pune Maternal Nutrition Study. J Nutr. 2001;131(4):1217–24.
15. Sun J, Xu B, Freeland-Graves J. Automated quantification of abdominal adiposity by magnetic resonance imaging. Am J Hum Biol. 2016;28(6):757–66.
16. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–70.
17. Wareham NJ, Phillips DI, Byrne CD, Hales CN. The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med. 1995;12(10):931.

18. World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i–xii, 1–253.
19. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014;37 Suppl 1:S14–80.
20. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation; 2006.
21. Yajnik CS, Bandopadhyay S, Bhalerao A, Bhat DS, Phatak SB, Wagh RH, et al. Poor In Utero Growth, and Reduced β-Cell Compensation and High Fasting Glucose From Childhood, Are Harbingers of Glucose Intolerance in Young Indians. Diabetes Care. 2021;44(12):2747–57.
22. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116(1):39–48.
23. Mao J, Gan S, Gong S, Zhou Q, Yu F, Zhou H, et al. Visceral fat area is more strongly associated with arterial stiffness than abdominal subcutaneous fat area in Chinese patients with type 2 diabetes. Diabetol Metab Syndr. 2024;16(1):123.
24. Emamat H, Jamshidi A, Farhadi A, Ghalandari H, Ghasemi M, Tangestani H. The association between the visceral to subcutaneous abdominal fat ratio and the risk of cardiovascular diseases: a systematic review. BMC Public Health. 2024;24(1):1827.
25. Chowdhury B, Lantz H, Sjostrom L. Computed tomography-determined body composition in relation to cardiovascular risk factors in Indian and matched Swedish males. Metabolism. 1996;45(5):634–44.
26. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1999;84(1):137–44.
27. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab. 2001;86(11):5366–71.
28. Chandalia M, Lin P, Seenivasan T, Livingston EH, Snell PG, Grundy SM, et al. Insulin resistance and body fat distribution in South Asian men compared to Caucasian men. PLoS One. 2007;2(8):e812.
29. Anand SS, Tarnopolsky MA, Rashid S, Schulze KM, Desai D, Mente A, et al. Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: the Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). PLoS One. 2011;6(7):e22112.
30. Iliodromiti S, McLaren J, Ghouri N, Miller MR, Dahlqvist Leinhard O, Linge J, et al. Liver, visceral and subcutaneous fat in men and women of South Asian and white European descent: a systematic review and meta-analysis of new and published data. Diabetologia. 2023;66(1):44–56.
31. Bjorntorp P. Fat cell distribution and metabolism. Ann N Y Acad Sci. 1987;499:66–72.
32. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab. 2002;87(10):4522–7.
33. Syme C, Abrahamowicz M, Leonard GT, Perron M, Pitiot A, Qiu X, et al. Intra-abdominal adiposity and individual components of the metabolic syndrome in adolescence: sex differences and underlying mechanisms. Arch Pediatr Adolesc Med. 2008;162(5):453–61.
34. Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Int J Epidemiol. 2007;36(1):220–5.

35. Thomas EL, Parkinson JR, Hyde MJ, Yap IK, Holmes E, Dore CJ, et al. Aberrant adiposity and ectopic lipid deposition characterize the adult phenotype of the preterm infant. Pediatr Res. 2011;70(5):507–12.
36. Mongraw-Chaffin M, Gujral UP, Kanaya AM, Kandula NR, Carr JJ, Anderson CAM. Relation of Ectopic Fat with Atherosclerotic Cardiovascular Disease Risk Score in South Asians Living in the United States (from the Mediators of Atherosclerosis in South Asians Living in America [MASALA] Study). Am J Cardiol. 2018;121(3):315–21.
37. Flowers E, Lin F, Kandula NR, Allison M, Carr JJ, Ding J, et al. Body Composition and Diabetes Risk in South Asians: Findings From the MASALA and MESA Studies. Diabetes Care. 2019;42(5):946–53.
38. Wells JC, Pomeroy E, Walimbe SR, Popkin BM, Yajnik CS. The Elevated Susceptibility to Diabetes in India: An Evolutionary Perspective. Front Public Health. 2016;4:145.
39. Yajnik CS, Fall CH, Coyaji KJ, Hirve SS, Rao S, Barker DJ, et al. Neonatal anthropometry: the thin-fat Indian baby. The Pune Maternal Nutrition Study. Int J Obes Relat Metab Disord. 2003;27(2):173–80.
40. Yajnik CS. Early life origins of the epidemic of the double burden of malnutrition: life can only be understood backwards. Lancet Reg Health Southeast Asia. 2024;28:100453.
41. Desoye G, Herrera E. Adipose tissue development and lipid metabolism in the human fetus: The 2020 perspective focusing on maternal diabetes and obesity. Prog Lipid Res. 2021;81:101082.
42. Orsso CE, Colin-Ramirez E, Field CJ, Madsen KL, Prado CM, Haqq AM. Adipose Tissue Development and Expansion from the Womb to Adolescence: An Overview. Nutrients. 2020;12(9).
43. Lin F, Sul HS. Distinct precursor landscape of subcutaneous and visceral fat in development and aging. Cell Rep. 2026;45(1):116706.
44. Modi N, Thomas EL, Uthaya SN, Umranikar S, Bell JD, Yajnik C. Whole body magnetic resonance imaging of healthy newborn infants demonstrates increased central adiposity in Asian Indians. Pediatr Res. 2009;65(5):584–7.
45. D'Angelo S, Yajnik CS, Kumaran K, Joglekar C, Lubree H, Crozier SR, et al. Body size and body composition: a comparison of children in India and the UK through infancy and early childhood. J Epidemiol Community Health. 2015;69(12):1147–53.
46. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11–8.
47. Agrawal S, Klarqvist MDR, Diamant N, Stanley TL, Ellinor PT, Mehta NN, et al. BMI-adjusted adipose tissue volumes exhibit depot-specific and divergent associations with cardiometabolic diseases. Nat Commun. 2023;14(1):266.
48. Thanaj M, Basty N, Cule M, Sorokin EP, Whitcher B, Srinivasan R, et al. Changes in abdominal subcutaneous adipose tissue thickness associate with disease and anthropometric factors. Int J Obes (Lond). 2025;49(9):1810–9.
49. Saxena A, Tiwari P, Wahi N, Soni A, Bansiwal RC, Kumar A, et al. Transcriptome profiling reveals association of peripheral adipose tissue pathology with type-2 diabetes in Asian Indians. Adipocyte. 2019;8(1):125–36.
50. Kumar A, Tiwari P, Saxena A, Purwar N, Wahi N, Sharma B, et al. The Transcriptomic Evidence on the Role of Abdominal Visceral vs. Subcutaneous Adipose Tissue in the Pathophysiology of Diabetes in Asian Indians Indicates the Involvement of Both. Biomolecules. 2020;10(9).
51. Saxena A, Mathur N, Tiwari P, Mathur SK. Whole transcriptome RNA-seq reveals key regulatory factors involved in type 2 diabetes pathology in peripheral fat of Asian Indians. Sci Rep. 2021;11(1):10632.

52. Vijay J, Gauthier MF, Biswell RL, Louiselle DA, Johnston JJ, Cheung WA, et al. Single-cell analysis of human adipose tissue identifies depot and disease specific cell types. Nat Metab. 2020;2(1):97–109.

Figure 1


All married non pregnant women in 6 villages
n = 2675
Consented to participate **n = 2466** (92%)
1994- 1996
797 pregnant women enrolled
Live births (n = **762**)
Deaths: n = 40
2013- 2014
18 year follow up
Of 722 alive, followed up **n = 663** (92%)
2013- 2014
18 year follow up
Of 663, Abdominal MRI done on **n = 599**
#
Scan excluded due to poor image quality, **n = 8**
Participant having MODY diabetes excluded , **n = 1**
Participants included in analysis, **n = 590**

Figure 2


a
MRI VAT area (cm2) in men and women
density
0.008
0.006
0.004
0.002
0.000
100
200
300
400
b
MRI ASAT area (cm2) in men and women
density
0.004
0.003
0.002
0.001
0.000
0
250
500
750
1000
c
MRI tot abd area (cm2) in men and women
density
0.003
0.002
0.001
0.000
0
250
500
750
1000
Men
Women

Figure 3


a
ASAT
VAT
Fasting glucose
OGTT 120min glucose
Insulinogenic Index
Matsuda Index (ISen)
Systolic BP
Diastolic BP
Triglyceride
Tot Cholesterol
HDL-c
LDL-c
TG:HDL
Leptin
Adiponectin
Total Leukocyte Count
CRP
EXPOSURE
OUTCOME
b
ASAT
VAT
Fasting glucose
OGTT 120min glucose
Insulinogenic Index
Matsuda Index (ISen)
Systolic BP
Diastolic BP
Triglyceride
Tot Cholesterol
HDL-c
LDL-c
TG:HDL
Leptin
Adiponectin
Total Leukocyte Count
CRP
EXPOSURE
OUTCOME
Positive
Negative
NS

Figure 4


MALES
FEMALES
BMI
ASAT
VAT
ASAT.VAT_Ratio
PMNS (18y)
UK.SA1 (23y)
UK.SA2 (24y)
MolSHARE (37y)
CRISIS (42y)
CURES (45y)
MASALA (55y)
-1
0
1
2
Standardized Mean (Z-score)

Figure 5


VAT-centric risk model in Western adult population
ASAT
VAT
Risk
Obese
Insulin resistant
Stroke
Heart Disease
Fatty Liver
245
mg/dL
Diabetes
Hypertension &
Inflammation
ASAT-dominant risk in young Indians
ASAT
VAT
Risk
Adverse metabolic risk profile at 18-years
Thin-fat
Insulin deficient
Rapid socio-economic & nutritional transition - DBM
120
mg/dL
High Glucose
Adipocytokines
High Leptin
Low Adiponectin
High Insulin
Secretion &
Low Sensitivity
Adverse
Lipid Profile
High TG
Low HDL
High Inflammation
CRP, TLC
140/90
Over 40
High Blood
Pressure